Skip to main content
DOUBLE MEDICAL TECHNOLOGY INC. logo

DOUBLE MEDICAL TECHNOLOGY INC. — Investor Relations & Filings

Ticker · 002901 ISIN · CNE1000032W7 LEI · 836800DECKX5CGFNMD42 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 963 across all filing types
Latest filing 2025-10-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002901

About DOUBLE MEDICAL TECHNOLOGY INC.

https://www.double-medical.com

Double Medical Technology Inc. specializes in the development, manufacturing, and distribution of medical devices, with a primary focus on orthopedic solutions. The company's extensive product portfolio includes trauma fixation systems, spinal implants, joint prosthesis, and neurosurgical devices. Additionally, it provides specialized surgical instruments and advanced wound care products. Double Medical emphasizes research and innovation to deliver clinically effective solutions for complex musculoskeletal conditions. Its manufacturing processes adhere to international quality standards, ensuring the reliability of its implants and instruments used in hospitals and surgical centers worldwide. The company serves a global market, providing comprehensive support for orthopedic surgeons through its diverse range of reconstructive and regenerative medical technologies.

Recent filings

Filing Released Lang Actions
福建天衡联合律师事务所关于大博医疗科技股份有限公司2024年股票期权激励计划首次授予股票期权第一个行权期行权条件成就及注销部分股票期权事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2024 stock option incentive plan of a company, specifically about the first exercise period conditions achievement and the cancellation of some stock options. It includes detailed legal review, approvals by the board and supervisory committees, audit confirmations, and compliance with relevant laws and regulations. The document is not a financial report, earnings release, or management discussion but a legal opinion related to stock option incentive plan execution and cancellation. This type of document fits best under Regulatory Filings (RNS) as it is a legal compliance and disclosure document that does not fall under other specific categories like Capital/Financing Update or Director's Dealing. The document length is 8856 characters, which is substantial and contains detailed legal content, not just an announcement or a brief notice. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2025-10-28 Chinese
关于召开2025年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2025 second extraordinary general meeting (临时股东大会) of the company 大博医疗科技股份有限公司. It includes information about the meeting time, location, agenda items (such as amendments to company articles and governance rules), voting procedures, registration details, and proxy forms. There is no financial data or results reported, nor is it a transcript or presentation. It is not an announcement of voting results but a notice to shareholders about the meeting and the proposals to be voted on. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2025-10-28 Chinese
第三届监事会第十九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Dabao Medical Technology Co., Ltd. It details the approval of the 2025 third quarter report, stock option incentive plans, use of idle funds for financial products, and amendments to the company charter. The document is relatively short (2111 characters) and repeatedly states that detailed reports or announcements are published separately on the official disclosure media and the CNINFO website. This indicates that the document itself is not the full quarterly report or detailed announcements but a meeting resolution summary and announcement. Therefore, it fits best as a Regulatory Filing (RNS) since it does not contain the full financial report or detailed data but is a formal regulatory announcement of supervisory board decisions and approvals.
2025-10-28 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 Third Quarter Report" of 大博医疗科技股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and shareholder information for the third quarter of 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis, which aligns with the definition of an Interim / Quarterly Report (IR). The document is over 13,000 characters, so it is not a mere announcement or publication notice. There is no indication that this is an annual report, audit report, or any other filing type. Therefore, the correct classification is Interim / Quarterly Report (IR). Q3 2025
2025-10-28 Chinese
信息披露管理制度（2025年10月）
Governance Information Classification · 95% confidence The document is titled "信息披露管理制度" which translates to "Information Disclosure Management System" and is issued by 大博医疗科技股份有限公司 (DaBo Medical Technology Co., Ltd.). The content extensively covers the company's policies, procedures, and responsibilities related to information disclosure, including definitions of periodic reports (annual, semi-annual, quarterly), interim reports, temporary reports, disclosure obligations, confidentiality, internal controls, and management responsibilities. It references regulatory frameworks such as the China Securities Regulatory Commission (CSRC) and Shenzhen Stock Exchange rules. The document is a detailed internal governance and compliance manual for managing information disclosure rather than an actual financial report or announcement. It does not contain financial statements, earnings data, or audit results. It also does not announce any specific event like a board change, capital update, or legal proceeding. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including information disclosure policies.
2025-10-28 Chinese
内部控制制度（2025年10月）
Governance Information Classification · 95% confidence The document is titled '内部控制制度' (Internal Control System) and is issued by 大博医疗科技股份有限公司. It extensively details the company's internal control policies, governance structure, risk management, internal audit, and compliance with relevant laws and regulations. The content focuses on the company's internal control framework rather than financial results or external announcements. It does not contain financial statements or earnings data, nor is it a brief announcement or a presentation. The document is a comprehensive internal governance and control policy document, which aligns with the category of Governance Information (CGR).
2025-10-28 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.